Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 8:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2401–2424 of 20,635 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Immune Dysfunction Clear all

Conditions: Asthma, Incentives, Tobacco Smoking
Interventions: Incentive plan, Smoking cessation; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 2 Years to 12 Years
Enrollment: 147 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Acute Lymphocytic Leukemia, Chronic Myeloid Leukemia, Acute Myelocytic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
Interventions: Isolex 300i Stem Cell Selection; Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 10 Years to 55 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: Oral BMS-663068 (pro-drug); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Medulloepithelioma, Childhood Meningioma, Childhood Mixed Glioma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Childhood Oligodendroglioma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: vorinostat, bortezomib, pharmacological study, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 1 Year to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 6
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York + 3 more

Conditions: Discoid Lupus Erythematosus, Systemic Lupus Erythematosus
Interventions: Tofacitinib citrate; Biological
Lead sponsor: Tufts Medical Center; Other
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections, Peripheral Nervous System Diseases
Interventions: Acetyl-L-carnitine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2007
U.S. locations: 10
States / cities: Palo Alto, California • Atlanta, Georgia • Honolulu, Hawaii + 5 more

Conditions: Diabetes, Diabetes Mellitus, Type 1
Interventions: No treatment given; Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 4 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Princeton, New Jersey

Conditions: Kidney Diseases, Kidney Diseases, Chronic, Urological Diseases, Glomerulonephritis, Glomerular Disease, Glomerulonephritis, IGA, Glomerulopathy, Immunoglobulin Disease
Interventions: zigakibart; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 8
States / cities: Denver, Colorado • Orlando, Florida • Iowa City, Iowa + 5 more

Conditions: Nodular Lymphocyte-Predominant Hodgkin Lymphoma
Interventions: Not listed
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 8 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 7
States / cities: Palo Alto, California • Aurora, Colorado • Boston, Massachusetts + 4 more

Conditions: Distress, Depression, Grief
Interventions: Psilocybin, Modified brief Supportive Expressive Group Therapy; Drug · Behavioral
Lead sponsor: Joshua Woolley; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Hematologic Neoplasms
Interventions: Stem cell transplantation, Fludarabine, Cyclophosphamide, Etoposide, Doxorubicin, Vincristine, Prednisone, Methotrexate, Cyclosporine, Apheresis; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2014
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Multiple Myeloma
Interventions: MLN9708; Drug
Lead sponsor: SCRI Development Innovations, LLC; Other
Eligibility: 18 Years to 70 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 4
States / cities: Denver, Colorado • Cincinnati, Ohio • Nashville, Tennessee + 1 more

Conditions: HIV Infections
Interventions: Zidovudine, Acyclovir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1994
U.S. locations: 8
States / cities: Boston, Massachusetts • Worcester, Massachusetts • Minneapolis, Minnesota + 3 more

Conditions: HIV Infections, STDs, Methamphetamine Abuse
Interventions: Theory-based counseling program; Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: San Diego, California

Conditions: HIV Infections, Mild Cognitive Impairment
Interventions: Mindfulness, Usual Care; Behavioral · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Grade 3b Follicular Lymphoma, Mantle Cell Lymphoma
Interventions: CD79b-19 CAR T cells, Cyclophosphamide, Fludarabine; Drug
Lead sponsor: Marcela V. Maus, M.D.,Ph.D.; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Systemic Lupus Erythematosus, Rheumatoid Arthritis, Multiple Sclerosis, Autoimmune Diseases, Chronic Inflammatory Syndromes, Immune Dysregulation
Interventions: Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN); Device · Drug
Lead sponsor: Truway Health, Inc.; Industry
Eligibility: Not listed
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2034
U.S. locations: 1
States / cities: New York, New York

Conditions: Thyroid Eye Disease
Interventions: VRDN-003, Placebo; Drug
Lead sponsor: Viridian Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 34
States / cities: Scottsdale, Arizona • Canoga Park, California • Huntington Beach, California + 25 more

Conditions: Hiv, Chlamydia, Gonorrhea, Relation, Interpersonal
Interventions: 2GETHER, Positive Affect Enhancement; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 256 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lymphoma, Chronic Lymphocytic Leukemia, Solid Tumors
Interventions: ABT-263, Ketoconazole; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Asthma
Interventions: Fenzian Device, Sham Device; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 12 Years to 80 Years
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 3
States / cities: Los Angeles, California • Baltimore, Maryland • Durham, North Carolina

Conditions: Lymphoma, Mantle-Cell
Interventions: Pirtobrutinib, Ibrutinib, Acalabrutinib, Zanubrutinib; Drug
Lead sponsor: Loxo Oncology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 36
States / cities: Anchorage, Alaska • Phoenix, Arizona • Los Angeles, California + 32 more

Conditions: HIV Infections
Interventions: p24CE1/2 pDNA vaccine, p24CE1/2 pDNA vaccine admixed with full-length p55^gag pDNA vaccine, Full-length p55^gag pDNA vaccine, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 65 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 14
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 9 more

Conditions: Type 1 Diabetes
Interventions: Insulet Artificial Pancreas (AP) System; Device
Lead sponsor: Insulet Corporation; Industry
Eligibility: 6 Years to 65 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Palo Alto, California • Santa Barbara, California • Walnut Creek, California + 1 more

Search by objective public record fields.

Financial Incentives to Reduce Pediatric Tobacco Smoke Exposures

Experimental Bone Marrow Transplant Protocol

A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)

Acetyl-L-Carnitine for the Treatment of NRTI-Associated Peripheral Neuropathy

An Observational Study to Assess Longitudinal Variation of Immune Biomarkers in Subjects at Risk for Development of Type 1 Diabetes

Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers

Determining the Feasibility of MLN9708 as Maintenance After Allogeneic Stem Cell Transplant for Multiple Myeloma

A Multicenter, Double Blind, Comparative Study of Zidovudine Alone Versus Zidovudine and Acyclovir as Treatment for HIV-Infected Patients With CD4+ Counts Less Than 200 Cells/mm3

Promoting Safer Sex in HIV+ Homosexual and Bisexual Men Who Use Methamphetamine

Feasibility of the Mindfulness-Based Stress Reduction Intervention for Black Women Living With HIV Supplement

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT)

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)

Randomized Trial of an HIV Prevention and Relationship Education Program for Young Male Couples

A Study to Assess the Effect of Ketoconazole on the Metabolism of ABT-263 (Navitoclax).

Fenzian Asthma Multicenter Outcomes Study

Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

HIV-1-Gag Conserved-Element DNA Vaccine (p24CE) Vaccine Study

Insulet Artificial Pancreas Early Feasibility Study